First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers
Accent Therapeutics
Accent Therapeutics
Mirati Therapeutics Inc.
Pheon Therapeutics
Novartis
Takeda
Tempus AI
Eli Lilly and Company
Alaunos Therapeutics
Mirati Therapeutics Inc.
Mirati Therapeutics Inc.
NantCell, Inc.
NextCure, Inc.
ADC Therapeutics S.A.
HiberCell, Inc.
Gilead Sciences
pharmaand GmbH
Eisai Inc.
Imunon
EndoVigilant Inc
MacroGenics
Gradalis, Inc.
Gilead Sciences
Takeda
Carponovum AB
US Oncology Research
Helsinn Healthcare SA
Pfizer
Generic Devices Consulting, Inc.
MedInnovation GmbH
Prism Pharma Co., Ltd.
GI View Ltd.
Novartis
Calando Pharmaceuticals
Photocure
Jennerex Biotherapeutics
Auron Healthcare GmbH
Novartis
Millennium Pharmaceuticals, Inc.